Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/857"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label |
"evidence_1954"
|
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: oral
study duration: 2 weeks
population: 18 nonsmoking white men
tested for known CYP450 polymorphisms? NO
ages: 19-27
description:
SUBJECTS: Eighteen nonsmoking white men participated in the study. The subjects were healthy as determined by medical history, physical examination, electrocardiography (ECG), and standard clinical chemistry and hematology tests. The subjects were not allowed to take any other medication for 2 weeks before or during the study.
METHODS: The study was conducted in two parts. In part 1, the 18 subjects were randomized into two parallel groups to receive in a double-blind fashion either 20 mg of citalopram (group A, n = 12; Cipramil, Lundbeck, Copenhagen, Denmark) or placebo (group B, n = 6) orally once daily for 14 days. Selegiline 10 mg (Eldepryl, Orion) once daily was added to both medications from day 11 to day 14. The groups were comparable with respect to demographic characteristics and baseline blood pressure and heart rate (Table 1). After a 5-week wash-out period, the 12 subjects that had received citalopram in part 1 of the study (group A) continued to part 2 to receive 10 mg of selegiline once daily for 4 days in an open cross-over mannger, in order to study the pharmacokinetics of selegiline without citalopram.
RESULTS: The mean AUC (0-5 h) of selegiline was 29% (p = 0.008; Table 3 and Fig. 4) lower in group A subjects when selegiline was administered concomitantly with citalopram compared with selegiline alone."
|
| dc:creator | |
| dc:date |
"02/09/2012 11:36:43"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ citalopram_increases_auc_selegiline, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1954 }